Steve Aselage - 31 May 2022 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Reporting relationship: Director
Issuer ticker: BCRX
Reported as of: 31 May 2022
Net transaction value: +$5,297
SEC form: 4
Accepted by SEC: 02 Jun 2022, 16:43:06 UTC
Prior SEC filing: 12 May 2022
Next SEC filing: 09 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Alane P. Barnes, by power of attorney

Filing notes and source

Key filing fact

Steve Aselage filed Form 4 for BIOCRYST PHARMACEUTICALS INC (BCRX) on 02 Jun 2022.

Key facts

This page summarizes Steve Aselage's Form 4 filing for BIOCRYST PHARMACEUTICALS INC (BCRX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 Jun 2022, 16:43.

Change

Previous filing in this sequence was filed on 12 May 2022.
Current net transaction value: +$5,297.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BCRX transaction

Common Stock

Award

Transaction value: $5,297
Shares: +569
Change %: +1.7%
Price: $9.31
Shares after: 33,728
Date: 31 May 2022
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250, prorated to $10,597.83 based on the increase in the annual retainer fee effective April 18, 2022.